Columvi (glofitamab-gxbm) — Medica

Initial criteria

• age ≥ 18 years
• patient has received one or more lines of systemic therapy
• patient has or will receive pretreatment with Gazyva (obinutuzumab intravenous infusion) before the first dose of Columvi
• medication is prescribed by or in consultation with an oncologist

Approval duration

1 year